Jefferies on Teva Pharma (TEVA): 'early, but investors should pay attention'
Tweet Send to a Friend
Jefferies analyst Dennis Ding reiterated a Buy rating and $40.00 price target on Teva Pharma (NYSE: TEVA)The analyst commented, "TEVA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
